Trial · NCT05208307
Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma
NCT05208307, Phase 2, Recruiting, Emory University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma. Trials, record NCT05208307. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05208307
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma
- NCT number
- NCT05208307
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 34 participants, estimated
- Lead sponsor
- Emory University
- Conditions
- Plasma Cell Myeloma
- Interventions
- Belantamab Mafodotin, Dexamethasone, Pomalidomide
- First posted
- 2022-01-26
- Last updated
- 2026-09-03
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Complete response rate | Up to 3 years | Assessed per International Myeloma Working Group criteria (best response during maintenance therapy). |
| Secondary | Incidence of adverse events | Up to 3 years | Toxicities of all patients will be tabulated as frequency and percentage. To evaluate the safety of the belantamab mafodotin, pomalidomide and dexamethasone (BPd) combination in the maintenance setting, proportion of safe patients will be estimated and its 95% confidence interval (CI) will be constructed by assuming binomial distribution. Adverse events will be graded using Common Terminology Criteria for Adverse Events (version 5.0). |
| Secondary | Very good partial response rate with BPd maintenance | Up to 3 years | Will be calculated as the proportion with 95% CI, assuming binomial distribution. |
| Secondary | Stringent complete response rate with BPd maintenance | Up to 3 years | Will be calculated as the proportion with 95% CI, assuming binomial distribution. |
| Secondary | Overall response with BPd maintenance | Up to 3 years | Will be calculated as the proportion with 95% CI, assuming binomial distribution. |
| Secondary | Progression free survival | Up to 3 years | Will be estimated with standard Kaplan-Meier method. |
| Secondary | Duration of response | Up to 3 years | Will be summarized with median and range. |
| Secondary | Overall survival (OS) | Up to 3 years | Will be estimated with standard Kaplan-Meier method. Both point and 95% CI of the median and other statistics (e.g., 6-month rate, 12-month rate, etc.) of OS will be calculated. |
| Secondary | Minimal residual disease (MRD) negativity rate | Up to 3 years | MRD detection will summarized using descriptive. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| P30CA138292 | Winship Cancer Institute Cancer Center Support Grant | RAMALINGAM, SURESH S | EMORY UNIVERSITY | NATIONAL CANCER INSTITUTE | 2009 to 2025 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05208307
GET https://conductscience.org/api/trials/v1/NCT05208307/registered